Literature DB >> 21558123

A common genetic variant in the 3'-UTR of vacuolar H+-ATPase ATP6V0A1 creates a micro-RNA motif to alter chromogranin A processing and hypertension risk.

Zhiyun Wei1, Nilima Biswas, Lei Wang, Maite Courel, Kuixing Zhang, Alex Soler-Jover, Laurent Taupenot, Daniel T O'Connor.   

Abstract

BACKGROUND: The catecholamine release-inhibitor catestatin and its precursor chromogranin A (CHGA) may constitute "intermediate phenotypes" in the analysis of genetic risk for cardiovascular disease such as hypertension. Previously, the vacuolar H(+)-ATPase subunit gene ATP6V0A1 was found within the confidence interval for linkage with catestatin secretion in a genome-wide study, and its 3'-UTR polymorphism T+3246C (rs938671) was associated with both catestatin processing from CHGA and population blood pressure. We explored the molecular mechanism of this effect by experiments with transfected chimeric photoproteins in chromaffin cells. METHODS AND
RESULTS: Placing the ATP6V0A1 3'-UTR downstream of a luciferase reporter, we found that the C (variant) allele decreased overall gene expression. The 3'-UTR effect was verified by coupled in vitro transcription/translation of the entire/intact human ATP6V0A1 mRNA. Chromaffin granule pH, monitored by fluorescence of CHGA/EGFP chimera during vesicular H(+)-ATPase inhibition by bafilomycin A1, was more easily perturbed during coexpression of the ATP6V0A1 3'-UTR C-allele than the T-allele. After bafilomycin A1 treatment, the ratio of CHGA precursor to its catestatin fragments in PC12 cells was substantially diminished, though the qualitative composition of such fragments was not affected (on immunoblot or matrix-assisted laser desorption ionization (MALDI) mass spectrometry). Bafilomycin A1 treatment also decreased exocytotic secretion from the regulated pathway, monitored by a CHGA chimera tagged with embryonic alkaline phosphatase. 3'-UTR T+3246C created a binding motif for micro-RNA hsa-miR-637; cotransfection of hsa-miR-637 precursor or antagomir/inhibitor oligonucleotides yielded the predicted changes in expression of luciferase reporter/ATP6V0A1-3'-UTR plasmids varying at T+3246C.
CONCLUSIONS: The results suggest a series of events whereby ATP6V0A1 3'-UTR variant T+3246C functioned: ATP6V0A1 expression probably was affected through differential micro-RNA effects, altering vacuolar pH and consequently CHGA processing and exocytotic secretion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21558123      PMCID: PMC3319682          DOI: 10.1161/CIRCGENETICS.111.959767

Source DB:  PubMed          Journal:  Circ Cardiovasc Genet        ISSN: 1942-3268


  40 in total

Review 1.  The vacuolar (H+)-ATPases--nature's most versatile proton pumps.

Authors:  Tsuyoshi Nishi; Michael Forgac
Journal:  Nat Rev Mol Cell Biol       Date:  2002-02       Impact factor: 94.444

2.  Mechanisms of pH regulation in the regulated secretory pathway.

Authors:  M M Wu; M Grabe; S Adams; R Y Tsien; H P Moore; T E Machen
Journal:  J Biol Chem       Date:  2001-06-11       Impact factor: 5.157

Review 3.  The chromogranin-secretogranin family.

Authors:  Laurent Taupenot; Kimberly L Harper; Daniel T O'Connor
Journal:  N Engl J Med       Date:  2003-03-20       Impact factor: 91.245

4.  Bafilomycin A1 inhibits the targeting of lysosomal acid hydrolases in cultured hepatocytes.

Authors:  K Oda; Y Nishimura; Y Ikehara; K Kato
Journal:  Biochem Biophys Res Commun       Date:  1991-07-15       Impact factor: 3.575

Review 5.  Genetic analysis of inherited hypertension in the rat.

Authors:  J P Rapp
Journal:  Physiol Rev       Date:  2000-01       Impact factor: 37.312

6.  Mutations in ATP6N1B, encoding a new kidney vacuolar proton pump 116-kD subunit, cause recessive distal renal tubular acidosis with preserved hearing.

Authors:  A N Smith; J Skaug; K A Choate; A Nayir; A Bakkaloglu; S Ozen; S A Hulton; S A Sanjad; E A Al-Sabban; R P Lifton; S W Scherer; F E Karet
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

7.  Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension.

Authors:  Daniel T O'Connor; Mala T Kailasam; Brian P Kennedy; Michael G Ziegler; Noboru Yanaihara; Robert J Parmer
Journal:  J Hypertens       Date:  2002-07       Impact factor: 4.844

8.  Organelle pH studies using targeted avidin and fluorescein-biotin.

Authors:  M M Wu; J Llopis; S Adams; J M McCaffery; M S Kulomaa; T E Machen; H P Moore; R Y Tsien
Journal:  Chem Biol       Date:  2000-03

9.  Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells.

Authors:  E J Bowman; A Siebers; K Altendorf
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

10.  Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells.

Authors:  T Yoshimori; A Yamamoto; Y Moriyama; M Futai; Y Tashiro
Journal:  J Biol Chem       Date:  1991-09-15       Impact factor: 5.157

View more
  10 in total

Review 1.  The emerging role of non-coding RNA in essential hypertension and blood pressure regulation.

Authors:  F Z Marques; S A Booth; F J Charchar
Journal:  J Hum Hypertens       Date:  2014-11-13       Impact factor: 3.012

2.  Heredity and cardiometabolic risk: naturally occurring polymorphisms in the human neuropeptide Y(2) receptor promoter disrupt multiple transcriptional response motifs.

Authors:  Zhiyun Wei; Kuixing Zhang; Gen Wen; Karthika Balasubramanian; Pei-an B Shih; Fangwen Rao; Ryan S Friese; Jose P Miramontes-Gonzalez; Geert W Schmid-Schoenbein; Hyung-Suk Kim; Sushil K Mahata; Daniel T O'Connor
Journal:  J Hypertens       Date:  2013-01       Impact factor: 4.844

3.  The myriad essential roles of microRNAs in cardiovascular homeostasis and disease.

Authors:  Ronald L Neppl; Da-Zhi Wang
Journal:  Genes Dis       Date:  2014-03-01

Review 4.  Non-coding RNAs and hypertension-unveiling unexpected mechanisms of hypertension by the dark matter of the genome.

Authors:  Kazuo Murakami
Journal:  Curr Hypertens Rev       Date:  2015

5.  A personalized, multiomics approach identifies genes involved in cardiac hypertrophy and heart failure.

Authors:  Marc Santolini; Milagros C Romay; Clara L Yukhtman; Christoph D Rau; Shuxun Ren; Jeffrey J Saucerman; Jessica J Wang; James N Weiss; Yibin Wang; Aldons J Lusis; Alain Karma
Journal:  NPJ Syst Biol Appl       Date:  2018-02-24

Review 6.  Non-Coding RNA in the Pathogenesis, Progression and Treatment of Hypertension.

Authors:  Christiana Leimena; Hongyu Qiu
Journal:  Int J Mol Sci       Date:  2018-03-21       Impact factor: 5.923

7.  Prevention of vascular calcification by the endogenous chromogranin A-derived mediator that inhibits osteogenic transdifferentiation.

Authors:  Setareh Orth-Alampour; Nathalie Gayrard; Silvia Salem; Àngel Argilés; Joachim Jankowski; Shruti Bhargava; Vera Jankowski; Bernard Jover; Cécile Notarnicola; Heidi Noels; Emiel P C van der Vorst; Christoph Kuppe; Michael Wolf; Claudia Goettsch; Wendy Theelen; Heike Bruck; Danilo Fliser; Joseph Loscalzo; Zhuojun Wu; Nikolaus Marx; Walter Zidek
Journal:  Basic Res Cardiol       Date:  2021-10-13       Impact factor: 17.165

8.  The regulated secretory pathway and human disease: insights from gene variants and single nucleotide polymorphisms.

Authors:  Wei-Jye Lin; Stephen R Salton
Journal:  Front Endocrinol (Lausanne)       Date:  2013-08-06       Impact factor: 5.555

9.  A polymorphic 3'UTR element in ATP1B1 regulates alternative polyadenylation and is associated with blood pressure.

Authors:  Megana K Prasad; Kavita Bhalla; Zhen Hua Pan; Jeffrey R O'Connell; Alan B Weder; Aravinda Chakravarti; Bin Tian; Yen-Pei C Chang
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

10.  miRNA-dependent target regulation: functional characterization of single-nucleotide polymorphisms identified in genome-wide association studies of Alzheimer's disease.

Authors:  Charlotte Delay; Benjamin Grenier-Boley; Philippe Amouyel; Julie Dumont; Jean-Charles Lambert
Journal:  Alzheimers Res Ther       Date:  2016-05-24       Impact factor: 6.982

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.